Distinguishing and Managing Early-Stage Alzheimer’s Disease: Leveraging Interdisciplinary Collaboration for Prompt Identification and Optimal Patient Management
The FDA approved donanemab for adults with early symptomatic Alzheimer's disease (AD), which includes people with mild cognitive impairment (MCI) as well as people with the mild dementia stage of AD, with confirmed amyloid pathology on July 2, 2024, after this program was filmed. In addition, new guidelines for the diagnosis of Alzheimer’s disease were published on June 28, 2024, recommending diagnosis based on biomarkers rather than written memory tests.
PROGRAM CHAIRS
Brad Dickerson, MD, MMSc, FAAN
Director, Massachusetts General Hospital
Frontotemporal Disorders Unit
Professor of Neurology, Harvard Medical School
Boston, MA
Liana Apostolova, MD, MSc, FAAN
Indiana University Distinguished Professor
Barbara and Peer Baekgaard Professor
of Alzheimer's Disease Research
Professor in Neurology, Radiology, Medical and Molecular Genetics
Indiana University School of Medicine
Department of Neurology
Indianapolis, IN
FACULTY PRESENTERS
Scott Kaiser, MD
Director of Geriatric Cognitive Health
Pacific Neuroscience Institute
Santa Monica, CA
Adjunct Professor
USC Leonard Davis School of Gerontology
Los Angeles, CA
Chi-Ying (Roy) Lin, MD, MPH, FAAN
Director, CurePSP Center of Care for PSP, CBD, and MSA
Assistant Professor of Neurology
Alzheimer's and Parkinson's Disease Centers
Baylor College of Medicine
Houston, TX
PROGRAM OVERVIEW
This enduring activity is designed to help Alzheimer’s disease and dementia providers diagnose AD earlier in the disease course through comprehensive history, physical and quantitative assessments, neuroimaging, and referral when appropriate. Through interactive case-based learning, our faculty will assist learners in developing strategies to improve multidisciplinary and clinician/patient communication to facilitate the best possible treatment outcomes.
TARGET AUDIENCE
This enduring activity is designed to meet the educational needs of healthcare providers involved in the diagnosis and continued care of patients with Alzheimer’s disease, including neurologists, geriatricians, psychiatrists, primary care physicians, nurses, and other multidisciplinary team members.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Implement strategies to overcome barriers to timely diagnosis of Alzheimer’s disease, addressing stigma, applying quantitative assessments, and integrating neuroimaging as well as specialty referral in clinical assessment
- Formulate strategies to optimize multidisciplinary communication and specialty referral
- Incorporate updates in clinical data to inform the identification of AD early in the disease process
- Implement shared decision-making (SDM) approaches to facilitate diagnosis and optimize management
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in this enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 2.0 ANCC contact hours.
PHARMACISTS AND PHARMACY TECHNICIANS (ACPE) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 2.0 knowledge-based CPE contact hours.
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.
COMMISSION ON DIETETIC REGISTRATION (CDR) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 2.0 CPEUs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Brad Dickerson, MD, MMSc, FAAN | Dr. Dickerson has nothing to disclose. |
| Liana Apostolova, MD, MSc, FAAN | Dr. Apostolova discloses that she has received grants from Alzheimer’s Association, AVID Pharmaceuticals, Eli Lilly, Life Molecular Imaging, NIH, and Roche Diagnostics. She is a consultant for Alnylam, Biogen, Corium, Eisai, Eli Lilly, Florida Department of Health, GE Healthcare, Genentech, IQVIA, NIH Biobank, Otsuka, Roche Diagnostics, Siemens, and Two Labs. She has received honoraria from American Academy of Neurology, APhA, CME Institute, Mayo Clinic, Med Learning Group, MillerMed, MJH Physician Education Resource, NACC CME, Ohio State University, PeerView, Purdue University, WebMD, and Weil Cornell. She serves on the Data Safety Monitoring or Advisory Boards for IQVIA, New Mexico Exploratory ADRC, NIA Grant R01 AG061111, UAB Nathan Shock Center, and US FDA. She has a leadership or fiduciary role for Alzheimer’s Association Science Program Committee, Beeson Program Committee, Med Sci Council Alzheimer’s Association Greater IN Chapter, and US FDA PCNS Advisory Committee. She has received equipment, materials, drugs, medical writing, gifts or other services from AVID Pharmaceuticals, Life Molecular Imaging, and Roche Diagnostics. |
| Scott Kaiser, MD | Dr. Kaiser discloses that he is a consultant for Independent Living Systems. He has received grants from National Institutes of Health and National Institute on Aging. He has ownership interest in Determined Health, Inc., and Determined Medical, Inc. He is on the Board of Directors for BrightFocus Foundation, and WISE & Healthy Aging. |
| Chi-Ying (Roy) Lin, MD, MPH, FAAN | Dr. Lin discloses that he is a speaker for MedScape and the American Academy of Neurology. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Mike Milano, MD, discloses that he has received royalties from Wolters Kluwer (UpToDate author royalties).
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Chris Drury, MA, MS, MBA, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator, for Med Learning Group, has nothing to disclose.
- Jacquelyn Sandfort, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: June 28, 2024
EXPIRATION DATE: June 28, 2025
Copyright ©2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
